Press Releases

Date Title and Summary  
Toggle Summary Research Documents Scalable Production, Survival Following Engraftment and Positive Impact On Cardiac Function in Infarcted Rats for Geron’s Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Company's Second Cell Type for Clinical Development – Cardiomyocytes for Treatment of Heart Failure – is Subject of Feature Presentation at ISSCR Annual Meeting Other Presentations Document Continued Progress in Geron's Development of Cellular Products for Spinal Cord Injury, Diabetes and
Toggle Summary Geron Increases Stake in TA Therapeutics Joint Venture
Joint Venture Company is Working Toward Filing of IND for Small Molecule Compound to Treat HIV/AIDS MENLO PARK, Calif., and HONG KONG, June 18, 2007 – Geron Corporation (Nasdaq: GERN) and the Biotechnology Research Corporation (BRC) of Hong Kong today announced that Geron has increased its stake in
Toggle Summary Geron´s Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
Data Presented at Pan Pacific Lymphoma Conference Support Continued Dose Escalation in Ongoing Chronic Lymphocytic Leukemia Trial New Studies in Multiple Myeloma and Non–Small Cell Lung Cancer to Start in the Coming Months MENLO PARK, Calif., June 12, 2007 – Geron Corporation’s (Nasdaq: GERN)
Toggle Summary Geron Corporation to Present at Needham & Company Biotechnology and Medical Technology Conference
MENLO PARK, Calif., Jun. 12, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 8:00 a.m. EDT on Wednesday, June 13, 2007, at the 6th Annual
Toggle Summary Research Indicates Geron´s Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
Study Findings Could Mean Significantly Lower Doses and/or Shorter Courses of Immunosuppression for Patients Treated with GRNOPC1 MENLO PARK, Calif., June 11, 2007 – Geron Corporation (Nasdaq: GERN) today announced the presentation of research studies indicating that GRNOPC1, the company’s human
Toggle Summary Geron Corporation to Present at Banc of America Health Care Conference
MENLO PARK, Calif., May 31, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 11:20 a.m. PDT on Friday, June 1, 2007, at the Banc of America 2007
Toggle Summary Geron Scientists and Collaborators Differentiate Human Embryonic Stem Cells Into Insulin-Producing Islet-Like Clusters
MENLO PARK, Calif., May 17, 2007 –– Geron Corporation (Nasdaq: GERN) today reported that its scientists and collaborators at the University of Alberta have differentiated human embryonic stem cells (hESCs) into islet–like clusters (ILCs) that secrete insulin in response to elevated glucose levels.
Toggle Summary Geron Corporation to Present at Rodman & Renshaw Healthcare Conference
MENLO PARK, Calif., May 11, 2007 – Geron Corporation (Nasdaq: GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 2:55 p.m. CEST (8:55 a.m.
Toggle Summary Geron Corporation to Present at UBS Global Generic & Specialty Pharmaceuticals Conference
Menlo Park, CA – May 7, 2007 –– Geron Corporation (Nasdaq: GERN) will be presenting an update of the company’s product development programs on Tuesday, May 8, 2007, at the UBS Global Generic & Specialty Pharmaceuticals Conference at 9:00 a.m. Eastern Time in New York City.
Toggle Summary Geron Corporation Reports 2007 First Quarter Financial Results
Menlo Park, Calif. – April 27, 2007 – Geron Corporation (Nasdaq: GERN) today reported financial results for the three months ended March 31, 2007. For the first quarter of 2007, the company reported operating revenues of $916,000 and operating expenses of $17.3 million, compared to $583,000 and